PCRX

Pacira BioSciences, Inc.

PCRX, USA

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

https://www.pacira.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PCRX
stock
PCRX

EcoR1 Capital LLC Acquires New Position in Pacira BioSciences, Inc. $PCRX MarketBeat

Read more →
PCRX
stock
PCRX

Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 15,896 Shares MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$30.1667

Analyst Picks

Strong Buy

1

Buy

1

Hold

3

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

51.21

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Low

1.61

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.75 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.42 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

31.73 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.78

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 112.04% of the total shares of Pacira BioSciences, Inc.

1.

BlackRock Inc

(17.3504%)

since

2025/06/30

2.

Vanguard Group Inc

(12.0312%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(6.1292%)

since

2025/08/31

4.

Renaissance Technologies Corp

(5.3315%)

since

2025/06/30

5.

D. E. Shaw & Co LP

(5.015%)

since

2025/06/30

6.

Dimensional Fund Advisors, Inc.

(4.7886%)

since

2025/06/30

7.

Balyasny Asset Management LLC

(4.7421%)

since

2025/06/30

8.

State Street Corp

(4.3412%)

since

2025/06/30

9.

Doma Perpetual Capital Management LLC

(4.015%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(3.042%)

since

2025/07/31

11.

Goldman Sachs Group Inc

(2.913%)

since

2025/06/30

12.

American Century Companies Inc

(2.6317%)

since

2025/06/30

13.

Geode Capital Management, LLC

(2.5442%)

since

2025/06/30

14.

iShares Russell 2000 ETF

(2.4719%)

since

2025/08/31

15.

Vanguard Small Cap Index

(2.3751%)

since

2025/07/31

16.

UBS Group AG

(2.2898%)

since

2025/06/30

17.

Jacobs Levy Equity Management, Inc.

(2.1916%)

since

2025/06/30

18.

Avantis US Small Cap Value ETF

(2.1721%)

since

2025/08/30

19.

Morgan Stanley - Brokerage Accounts

(2.1144%)

since

2025/06/30

20.

Polar Capital Holdings PLC

(2.0263%)

since

2025/06/30

21.

Polar Capital Healthcare Opports Inc

(1.6744%)

since

2025/07/31

22.

Vanguard Small Cap Value Index Inv

(1.5316%)

since

2025/07/31

23.

J. Goldman & Co LP

(1.4612%)

since

2025/06/30

24.

Northern Trust Corp

(1.3037%)

since

2025/06/30

25.

Charles Schwab Investment Management Inc

(1.2687%)

since

2025/06/30

26.

DFA US Small Cap Value I

(1.2475%)

since

2025/07/31

27.

Wellington Management Company LLP

(1.2143%)

since

2025/06/30

28.

Millennium Management LLC

(1.1462%)

since

2025/06/30

29.

Vanguard Institutional Extnd Mkt Idx Tr

(1.1039%)

since

2025/07/31

30.

Impax Small Cap Institutional

(1.0461%)

since

2025/07/31

31.

Impax US Small Cap Strategy Composite

(1.0461%)

since

2025/07/31

32.

Fidelity Small Cap Index

(1.0279%)

since

2025/06/30

33.

HBM Healthcare Investments AG Ord

(1.0044%)

since

2025/06/30

34.

iShares S&P Small-Cap 600 Value ETF

(0.9603%)

since

2025/08/31

36.

iShares Russell 2000 Value ETF

(0.8295%)

since

2025/08/31

37.

Pacer US Small Cap Cash Cows 100 ETF

(0.7491%)

since

2025/08/29

38.

Small Cap Core Equity Composite

(0.6677%)

since

2025/07/31

39.

DWS Small Cap Core S

(0.6677%)

since

2025/07/31

40.

Vanguard Tax-Managed Small Cap Adm

(0.6605%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.882

Latest Release

Date

2025-09-30

EPS Actual

0.7

EPS Estimate

0.65

EPS Difference

0.05

Surprise Percent

7.6923%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.